Semaglutide and Blood Pressure Meds: Why Dizziness Risk Is Rising

A New Safety Signal in GLP-1 Therapy

GLP-1 agonists have revolutionized the landscape of metabolic health, offering transformative benefits for individuals managing type 2 diabetes and obesity. Medications containing semaglutide, tirzepatide, and liraglutide have become household names, with brands like Ozempic, Wegovy, and Mounjaro changing lives across the globe. However, as usage expands, so does the need for rigorous safety monitoring.

Recent findings from Northwestern Medicine have brought a specific interaction to the forefront of clinical attention. Researchers are flagging a potential safety concern tied to GLP-1 medications and blood pressure management. A new study tracked more than 42,000 adults who started semaglutide, tirzepatide, or liraglutide while taking multiple blood pressure drugs, revealing a significant uptick in hypotensive episodes.

While these medications remain highly beneficial to many patients, the data underscores the importance of close clinical supervision, particularly for those already managing hypertension. This article breaks down the study findings, explains the physiological mechanisms at play, and offers practical guidance for patients navigating this complex medication landscape.

The Northwestern Medicine Study: What They Found

The research, presented at the ENDO 2026 annual meeting of the Endocrine Society, offers a large-scale look at real-world outcomes. By tracking over 42,000 adults, the authors were able to identify patterns that smaller studies might miss. The core of the investigation focused on hypotensive episodes, defined broadly to include dizziness, fainting, falls, low blood pressure diagnoses, and very low blood pressure readings.

The timeline of the data is particularly telling. The overall rate of these events jumped from 8.7% to 10.2% within the first six months of starting GLP-1 therapy. Crucially, this increased risk remained significant at the 12-month mark, suggesting this is not merely a transient adjustment period but a sustained interaction between the drug classes.

Dr. Micah Eimer, a senior study author and clinical assistant professor of medicine at Northwestern University Feinberg School of Medicine, emphasizes that the medical community must remain vigilant. He is a proponent of GLP-1s, noting their massive potential, but he stresses the need to watch out for hypotensive events in select patients because there is the potential to do harm.

Key Statistics on Hypotensive Episodes

To understand the scale of this risk, it is helpful to look at the specific data points gathered during the study. While the absolute increase may seem modest, the volume of patients involved makes the public health implication significant. The following table summarizes the key findings from the study cohort.

Why Does This Interaction Occur?

Understanding the mechanism behind this interaction is vital for patients and providers. One might assume that the drop in blood pressure is simply a result of weight loss, as shedding pounds often reduces cardiovascular strain. However, the researchers found that the increase in hypotensive events could not be explained by weight loss alone.

Beyond Weight Loss: The Hemodynamic Impact

GLP-1 medications work by mimicking the hormone glucagon-like peptide-1, which regulates appetite and glucose metabolism. Beyond the gut, these drugs have systemic effects, including potential vasodilation (widening of blood vessels) and changes in heart rate. When combined with antihypertensive medications, which are designed to lower blood pressure, the cumulative effect can push blood pressure levels too low.

This is particularly relevant for patients on multiple blood pressure drugs. The synergy between the two medication classes can lead to symptomatic hypotension, manifesting as dizziness, lightheadedness, or fainting. This risk is not theoretical; it is a documented physiological response that requires proactive management.

Who Is Most at Risk?

Not every patient taking these medications will experience these side effects. The study identified specific demographics that face a higher probability of adverse hypotensive events. Recognizing these risk factors allows for more personalized care plans and proactive monitoring.

• Adults 65 and Older: Aging naturally affects blood pressure regulation and vascular elasticity. Older adults may have less reserve to handle sudden drops in blood pressure, making them more susceptible to falls and fainting.
• People with Type 2 Diabetes: Individuals with diabetes often have underlying autonomic neuropathy, which can impair the body's ability to regulate blood pressure automatically. Adding a GLP-1 to their regimen may exacerbate existing regulatory issues.
• Patients on Multiple BP Meds: Those already on a complex regimen of antihypertensives are at the highest risk. The additive effect of lowering blood pressure through two different pathways increases the likelihood of hypotension.

Managing Safety: Monitoring and Medication Adjustments

The findings do not suggest that patients should stop their medications abruptly. Instead, they highlight the necessity of a structured approach to safety. Dr. Eimer specifically noted that he is particularly worried about the risk to patients who obtain GLP-1s without direct and ongoing clinical supervision.

Practical Steps for Patients

Patients can take several practical steps to mitigate risk while continuing their treatment. Communication with your healthcare provider is the first and most important step. If you notice symptoms, do not ignore them.

1. Monitor Blood Pressure Regularly: Keep a log of your blood pressure readings, especially when starting a new dose or adding a GLP-1 to your regimen. Look for trends rather than isolated readings.
2. Hydrate Consistently: GLP-1s can sometimes cause gastrointestinal side effects like nausea, which may lead to dehydration. Dehydration lowers blood volume, compounding the risk of hypotension.
3. Change Positions Slowly: If you feel dizzy when standing up, move slowly from lying to sitting, then to standing. This gives your cardiovascular system time to adjust.
4. Track Symptoms: Use a health tracking tool to log dizziness, fainting, or falls alongside your medication doses.

The Role of Clinical Supervision

The presentation of this data at ENDO 2026 serves as a reminder that research is often preliminary until fully peer-reviewed and published in major journals. However, the signal is strong enough to warrant caution. Dr. Eimer's message is clear: doctors need to closely monitor those who are already on multiple blood pressure drugs.

This is where digital health tools become invaluable. Platforms like Shotlee can help patients and providers collaborate more effectively. By using Shotlee to track your symptoms, doses, and blood pressure readings, you create a comprehensive data set that can be shared with your doctor. This allows for more informed decisions regarding dose adjustments or medication changes.

For example, if your Shotlee logs show a pattern of dizziness correlating with dose increases, your provider might consider a slower titration schedule or a review of your antihypertensive regimen. This data-driven approach ensures that the benefits of weight loss and glucose control are not outweighed by safety risks.

Conclusion

The intersection of GLP-1 therapy and blood pressure management is a complex area of medicine that requires careful navigation. While the study from Northwestern Medicine highlights a real risk of dizziness and fainting, it also reinforces the importance of informed, supervised care. For the majority of patients, the benefits of GLP-1s outweigh the risks, provided that potential side effects are monitored closely.

By understanding the specific risks associated with your medication profile, staying hydrated, and maintaining open communication with your healthcare team, you can safely pursue your health goals. Always seek personalized medical advice for individual healthcare decisions, as individual factors can vary greatly from the general trends presented in research.

Frequently Asked Questions

1. Is the risk of dizziness permanent if I take GLP-1s with blood pressure meds?

The risk is not necessarily permanent but is dose-dependent and time-sensitive. The study showed the risk remained significant at 12 months, but symptoms often stabilize as your body adjusts. Your doctor may adjust your blood pressure medication dosage to compensate for the GLP-1's effects.

2. Can I stop taking my blood pressure medication if I start Ozempic?

Do not stop or adjust your blood pressure medication without consulting your doctor. In some cases, weight loss from GLP-1s may lower your blood pressure naturally, requiring a reduction in BP meds. This must be done under medical supervision to avoid dangerous drops in blood pressure.

3. Which GLP-1 medications were included in the Northwestern Medicine study?

The study specifically tracked adults who started semaglutide, tirzepatide, or liraglutide. These are the active ingredients found in brands such as Ozempic, Wegovy, Mounjaro, and Victoza.

4. How can I track my symptoms to share with my doctor?

You can use health tracking apps like Shotlee to log your daily blood pressure readings, medication doses, and any episodes of dizziness or fainting. This data provides a clear picture of your health trends over time, making clinical visits more productive.

5. Does this study apply to people without diabetes?

The study noted that the risk was highest in people with type 2 diabetes, but the interaction between GLP-1s and blood pressure medications can affect anyone on those drugs. However, those with diabetes may be at higher risk due to underlying autonomic nervous system changes.